News
LXO Group publishes its latest ESG report
LXO Group is proud to announce the publication of its latest ESG report. The report details the company's efforts and achievements over the past year in terms of sustainability, ethics and social commitment.
13 Sep 2024
LXO Group announces the acquisition of prescription drug Nimotop® from Bayer
Press Release, november 06th, 2023 - Laboratoire X.O ("LXO"), is pleased to announce the acquisition of prescription drug Nimodipine under the brand name Nimotop® from Bayer, for several markets across different regions excluding Mainland China.
6 Nov 2023
Laboratoire XO is moving!
To support its growth, Laboratoire XO is moving to new premises and reaching for the sky!
10 Jul 2023
Laboratoire XO moves into a new phase of its growth with the support of Stanley Capital
Press Release, october 04th, 2022 - Stanley Capital Partners (SCP) has acquired a majority stake in French pharmaceutical group Laboratoire XO (Lab XO). Debt was provided by US giant Ares Management.
4 Oct 2022